Akebia Therapeutics, Inc. (AKBA) vs Eupraxia Pharmaceuticals Inc. (EPRX)
A side-by-side comparison of Akebia Therapeutics, Inc. and Eupraxia Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKBA
Akebia Therapeutics, Inc.
$0.88HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
EPRX
Eupraxia Pharmaceuticals Inc.
$7.96HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — AKBA vs EPRX
growth of $100 · dividends reinvested · last 2yAKBA -38.9% (-21.8%/yr)EPRX +162.7% (+62.1%/yr)EPRX compounded faster over this window
AKBA EPRX
AKBA vs EPRX: by the numbers
- •EPRX is the larger company ($267M vs $237M market cap).
- •Both run net losses; EPRX's is the smaller (0.00% vs -13.54% net margin).
Metrics side by side
Valuation
| Metric | AKBA | EPRX |
|---|---|---|
| P/S ratio | 1.08 | N/A |
| P/B ratio | 9.47 | 2.62 |
| FCF yield | 16.96% | N/A |
Profitability
| Metric | AKBA | EPRX |
|---|---|---|
| Gross margin | 79.48% | 0.00% |
| Operating margin | 9.95% | 0.00% |
| Net margin | -13.54% | 0.00% |
| ROE | -118.58% | -38.33% |
| ROIC | -7.08% | -43.56% |
Growth (annualized)
| Metric | AKBA | EPRX |
|---|---|---|
| Revenue CAGR (5Y) | -0.26% | N/A |
| Total return CAGR (5Y) | -20.07% | N/A |
Go deeper
Dig into the metrics
Akebia Therapeutics ROEEupraxia Pharmaceuticals ROEAkebia Therapeutics operating marginEupraxia Pharmaceuticals operating marginAkebia Therapeutics revenue growthEupraxia Pharmaceuticals revenue growthAkebia Therapeutics free cash flowEupraxia Pharmaceuticals free cash flow
Akebia Therapeutics & Eupraxia Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.